- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Biophore India Pharma, Akum Drugs and Pharma and 1 other ink pact for research of range of products for multiple therapies
New Delhi: Akums Drugs & Pharmaceuticals has announced that it has partnered with Leiutis Pharmaceuticals LLP and Biophore India Pharmaceuticals for the research and development of a range of products for multiple therapies.
The companies will look at products to cater to various segments like CNS (Central Nervous System) disorders, pain management, and hormonal disorders.
The focus of the companies in this partnership is to synergise capabilities, leverage research, and bring innovative products in specific therapeutic areas, within the next five years, both in India and other global markets and with the first few products expected to be commercialised in the next two years, the drug contract development and manufacturing organisation said in a statement.
''A significantly large number of patients suffer from diseases in India and globally, requiring treatment for several years and often having suboptimal experience with the available treatment options.
''In association with Leiutis and Biophore, we are committing to bringing unique products made available to the physicians and patients for improved clinical outcomes,'' Akums Founder and Promoter Sanjeev Jain said.
This tripartite association will see Akums manufacture and commercialise the products created by Leiutis and Biophore.
Read also: Akums Drugs and Pharma expects to touch Rs 10,000 crore turnover in next five years
Read also: Akum Pharma gets CDSCO panel nod to manufacture, market antihypertensive FDC drug
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751